				Disclosure of	transfers of va	lue made by Spa	rk during 2020	in Germany						
EFPIA templ Date of publication: 30/06/2														
	For further information please go to https://www.sparktx.com/we-are-spark/corporate-social-responsibility-ethics-and-patient-safety/efpia-transparency/ or contact Sunshine@sparktx.com/we-are-spark/corporate-social-responsibility-ethics-and-patient-safety/efpia-transparency/ or contact Sunshine@sparkty.com/we-are-sparkty/corporate-social-responsibility-ethics-and-patient-safety/ or contact Sunshine@sparkty/corporate-social-responsibility-ethics-and-patient-safety/ or contact Sunshine@sparkty/corporate-social-responsibility-ethics-and-patient-safety/ or contact Sunshine@sparkty/corporate-social-responsibility-ethics-and-patient-safety/ or contact Sunshine@sparkty/corporate-social-responsibility-ethics-and-patient-safety/ or contact Sunshine@sparkty/corporate-social-responsibility/ or contact Sunshine@sparkty/corporate-social-responsibility/ or contact Sunshine@sparkty/ or contact Sunshine@sparkty/corporate-social-responsibility													
	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation	Euros		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
			<u> </u>							<u> </u>				
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A			12803.06	186.04	12,989.10 €		
	Number of Recipients in aggregate disclosure - Art. 3.02 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A N/A	N/A N/A			3 100%	33%			
	76 or the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					IN/A	IN/A			10076	33 /6		İ	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
HCOs	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
Ī	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02													
	Number of Recipients in aggregate disclosure - Art. 3.02													
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02													
R &D	AGGREGATE DISCLOSURE													
	Tour of Value or December 2 December 2													
	Transfers of Value re: Research & Development											4,200.00 €		

latest update: 11 December 2013 v1